|
Market Closed -
London S.E.
11:35:21 2026-09-18 am EDT
|
5-day change | 1st Jan Change | ||
| 1,877.50 GBX | -1.18% |
|
+6.04% | +2.90% |
| Sep. 18 | European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading | MT |
| Sep. 18 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Market Cap | 75.23B 101B 87.74B 82.85B 141B 9,655B 142B 992B 383B 4,909B 378B 370B 15,794B | P/E 2026 * |
14.4x | P/E 2027 * | 12x |
|---|---|---|---|---|---|
| Enterprise Value | 95.91B 128B 112B 106B 180B 12,309B 180B 1,265B 488B 6,258B 482B 471B 20,136B | EV / Sales 2026 * |
2.83x | EV / Sales 2027 * | 2.63x |
| Free-Float |
92.75% | Yield 2026 * |
3.71% | Yield 2027 * | 3.99% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | -1.18% | ||
| 1 week | +6.04% | ||
| Current month | +1.29% | ||
| 1 month | -0.56% | ||
| 3 months | -2.37% | ||
| 6 months | -4.82% | ||
| Current year | +2.90% |
| 1 week | 1,789.5 |  | 1,912 |
| 1 month | 1,770 | | 1,937 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,455 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/9/26 | Free | Compliance Officer | 7 | 0.0000% | ||
| 9/9/26 | Buy | Executive/Senior Manager | 7 | 0.0000% | ||
| 9/9/26 | Free | Executive/Senior Manager | 7 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.18% | +6.04% | +27.46% | +24.72% | 101B | |
| +0.04% | +3.34% | +51.12% | +101.82% | 1,028B | |
| -0.09% | +1.66% | +55.02% | +66.18% | 651B | |
| -0.02% | +2.66% | +18.91% | +71.47% | 466B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 346B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 266B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 259B | |
| +1.55% | +2.20% | +39.81% | +46.55% | 208B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 191B | |
| -0.52% | +4.45% | +32.12% | +98.51% | 186B | |
| Average | +0.06% | +3.53% | +26.28% | +43.24% | 370.24B | |
| Weighted average by Cap. | +0.19% | +3.17% | +34.94% | +60.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 45.39B 39.58B 37.37B 63.58B 4,355B 63.84B 448B 173B 2,214B 170B 167B 7,124B | 35.5B 47.49B 41.41B 39.1B 66.52B 4,556B 66.8B 468B 181B 2,317B 178B 174B 7,454B |
| Net income | 5.35B 7.15B 6.24B 5.89B 10.02B 686B 10.06B 70.54B 27.22B 349B 26.87B 26.27B 1,123B | 6.28B 8.4B 7.33B 6.92B 11.77B 806B 11.82B 82.89B 31.99B 410B 31.57B 30.87B 1,319B |
| Net Debt | 20.68B 27.66B 24.12B 22.77B 38.75B 2,654B 38.91B 273B 105B 1,349B 104B 102B 4,342B | 17.97B 24.03B 20.96B 19.79B 33.66B 2,306B 33.81B 237B 91.46B 1,172B 90.27B 88.27B 3,772B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | GBX 1,877.50 | -1.18% | 15,668,959 |
| 26-09-17 | GBX 1,900.00 | +1.85% | 9,894,223 |
| 26-09-16 | GBX 1,865.50 | +0.62% | 7,165,786 |
| 26-09-15 | GBX 1,854.00 | -0.03% | 4,902,189 |
| 26-09-14 | GBX 1,854.50 | +4.74% | 4,365,927 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
